Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings Inc (NYSE American: SENS) is a pioneer in long-term implantable continuous glucose monitoring systems, transforming diabetes care through innovative medical technology. This news hub provides investors and healthcare professionals with timely updates on corporate developments, regulatory milestones, and clinical advancements.
Access official press releases covering financial results, product approvals, and strategic partnerships alongside analysis of key operational updates. Our curated news collection includes updates on Eversense CGM system enhancements, international market expansions, and clinical study outcomes.
Stay informed about critical developments including FDA submissions, European regulatory updates, and partnership announcements with global healthcare distributors. Bookmark this page for direct access to primary source materials essential for tracking Senseonics' progress in medical device innovation.
Senseonics Holdings (NYSE: SENS) has announced the pricing of a $50 million public offering of common stock, consisting of 100,000,000 shares priced at $0.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 15,000,000 shares. In a concurrent private placement, Abbott Laboratories will purchase shares at $0.50 per share, representing 4.99% of Senseonics' post-offering outstanding common stock.
The offering is expected to close on May 19, 2025, with TD Cowen and Barclays acting as joint book-running managers. The net proceeds will be used to fund the ongoing launch of Eversense 365 and pipeline product development, along with working capital and general corporate purposes.
Senseonics Holdings (NYSE: SENS) has announced a public offering of common stock aiming to raise $50 million, along with a concurrent private placement. The company will grant underwriters a 30-day option to purchase an additional 15% of the total shares offered. Abbott Laboratories has agreed to purchase up to $25 million of shares in a separate private placement at the public offering price.
The offering is being managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners. The proceeds will be used to fund the ongoing launch of Eversense 365, continue pipeline product development, and support working capital and general corporate purposes.
Senseonics Holdings, a pioneer in medical technology focusing on implantable continuous glucose monitoring (CGM) systems for diabetes patients, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss Q1 2025 performance. Investors can participate through multiple channels:
- Conference call: US/Canada: 1-800-343-4136
- International: 1-203-518-9843
- Passcode: SENSQ1
- Webcast: Available on www.senseonics.com under Investor Relations
The webcast will be archived on the company's website for future reference. Participants are advised to dial in 5-10 minutes before the start time.
Sequel Med Tech and Senseonics have partnered to create the first Automated Insulin Delivery (AID) System compatible with a one-year continuous glucose monitor. The integration combines Sequel's twiist™ AID System with Senseonics' Eversense® 365, the world's first and only one-year CGM system.
Key highlights:
- Launch expected in Q3 2025
- System offers enhanced diabetes management tools
- twiist will be compatible with both Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor
- Eversense 365 received FDA iCGM clearance in September 2024
The collaboration aims to provide greater flexibility and personalization for people with type 1 diabetes. This integration marks a significant advancement in diabetes care, combining Senseonics' long-duration CGM technology with Sequel's state-of-the-art insulin delivery system to potentially improve glucose control and increase convenience for users.
Senseonics Holdings (NYSE: SENS) reported Q4 and full year 2024 financial results, highlighting significant achievements in their diabetes care technology. The company's Eversense® 365 CGM system received FDA approval and launched in the US, leading to a 56% increase in global patient base to approximately 6,000 patients.
Q4 2024 revenue reached $8.3 million with a net loss of $15.5 million ($0.02 per share). Full-year 2024 revenue was $22.5 million with a net loss of $78.6 million ($0.12 per share). December marked the highest monthly new patient shipments at approximately 600.
Key highlights include:
- Exceeded 2,400 annual US Eversense prescribers in 2024
- 81% of patients switched from competitive CGMs
- Completed CE Mark application for Eversense 365 in EU
- Executed restructuring with $10M target cost reduction for 2025
For 2025, Senseonics projects global net revenue of $34-38 million with gross margins between 25-30%.
Senseonics Holdings (NYSE: SENS) and Ascensia Diabetes Care have announced the integration of SweetSpot™ software with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This integration enables endocrinology practices partnered with SweetSpot to enhance patient care through seamless data review from the world's first and only One Year CGM system.
SweetSpot's platform combines centralized diabetes device data management with clinical support services. Their virtual team of Certified Diabetes Care and Education Specialists performs monthly CGM data reviews and coordinates with healthcare providers on treatment plans. The integration allows for personalized support between appointments and helps ensure timely treatment adjustments.
The partnership aims to improve glycemic control while offering practices automated capture of reimbursable care events. Eversense 365, developed by Senseonics and distributed by Ascensia, provides one year of accurate monitoring with minimal interruptions as the only implantable CGM available.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for diabetes patients, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA.
The company will deliver a corporate overview and conduct one-on-one meetings during the conference on Tuesday, March 4, 2025, at 3:10 pm ET. Interested parties can access both live and recorded webcasts of the presentation through the 'Investor Relations' section of Senseonics' website at www.senseonics.com.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has scheduled its fourth quarter and full year 2024 earnings release for March 3, 2025, after market close.
The company will host a conference call at 4:30 P.M. Eastern Time on the same day to discuss the financial results. Investors can access the call by dialing 1-800-445-7795 (US/Canada) or 1-785-424-1699 (International) using passcode SENSQ4. A concurrent webcast will be available on the company's website under the Investor Relations section and will be archived for future reference.
Senseonics Holdings (NYSE: SENS) has submitted a CE Mark registration for its Eversense 365 CGM system, the world's first one-year continuous glucose monitoring system. The device, already FDA-approved and launched in the US in October 2024, could soon be commercialized across EU member countries through Ascensia Diabetes Care.
The Eversense 365 system offers significant advantages over traditional short-term CGMs, including: year-long duration, removable smart transmitter, trusted alerts with exceptional accuracy, comfortable silicone-based adhesives, and weekly calibration requirements. Following CE Mark approval, the company plans distribution in Germany, Italy, Spain, Poland, Switzerland, and Sweden.
The system is cleared in the US as an integrated CGM (iCGM) system, compatible with insulin pumps for automated insulin delivery (AID) systems, with ongoing partnership discussions with pump manufacturers.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
